Key result
Levodopa appears to modify the clinical course of neuroleptic malignant syndrome in a small case series.
Levodopa may modify the course of neuroleptic malignant syndrome, a severe complication of antipsychotic therapy.
Answers are grounded in this paper and cite their sources.
Levodopa may be considered in neuroleptic malignant syndrome; hypothesis-generating from case reports and requires prospective validation.
Three cases of the neuroleptic malignant syndrome, which complicated treatment with haloperidol, fluphenazine and, in one case, with several drugs, are described. All three patients recovered and, in two, levodopa appeared to modify the course of the condition. In one patient, myoclonus was present and has persisted. The pharmacological mechanisms involved in this syndrome are discussed.
No takes yet. Share an insight, caveat, or question.
Knezevic et al. (1984) studied this question. Levodopa appeared to modify the clinical course of neuroleptic malignant syndrome in two out of three patients who recovered from the condition.
Synapse has enriched 10 related papers. Consider them for comparative context: